AbbVie (ABBV) Announces FDA Approval of RINVOQ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Abbvie (ABBV) PT Raised to $150 at Cowen Following Rinvoq Approval
January 18, 2022 6:25 AM ESTCowen analyst Steve Scala raised the price target on Abbvie (NYSE: ABBV) to $150.00 (from $130.00) while maintaining an Outperform rating after Rinvoq was approved in atopic dermatitis.
The analyst commented, "Rinvoq was approved in atopic dermatitis on Friday. The timing and details... More
